Roche Venture Fund
Investor profile
Venture capital
Roche Venture Fund has backed 9 European tech companies across 11 funding rounds between 2013 and 2026, joining rounds totalling €462M. Most active in Healthtech. Data as of 4 Nov 2026.
Also recorded as: Roche Ventures
Deals
11
distinct rounds
Companies
9
backed
Active span
2013–2026
14 yrs
Total round €
€462M
sum of rounds joined
Deals by year
distinct rounds / yearRoche Venture Fund — deals by year — interactive chart.
Data table
| Roche Venture Fund — deals by year | |
|---|---|
| 2013 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 1 |
Top sectors
by dealsRoche Venture Fund — top sectors — interactive chart.
Data table
| Roche Venture Fund — top sectors | |
|---|---|
| Healthtech | 11 |
Stages
by dealsRoche Venture Fund — stages — interactive chart.
Data table
| Roche Venture Fund — stages | |
|---|---|
| Series A | 4 |
| Series B | 4 |
| Other | 2 |
| Series C | 1 |
Countries
by dealsRoche Venture Fund — countries — interactive chart.
Data table
| Roche Venture Fund — countries | |
|---|---|
| UK | 4 |
| France | 2 |
| Switzerland | 2 |
| Austria | 1 |
| Denmark | 1 |
| Spain | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Sofinnova Partners5
- 5AM Ventures2
- Novartis Venture Fund2
- Novo Holdings2
- Ysios Capital2
- AdBio partners1
- Agent Capital1
- Asabys Partners1
- BioGeneration Ventures1
- Boehringer Ingelheim Venture Fund1
- Bristol Myers Squibb1
- Catalio1
- Columbus Venture Partners1
- Draper Esprit1
- Eli lilly and company1
- Epidarex Capital1
- EQT Life Sciences1
- Gilde Healthcare1
- HealthCap1
- INKEF Capital1
- IP Group1
- iSEED Ventures1
- JDRF T1D Fund1
- Jeito Capital1
- Kurma Partners1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| GlycoEra | Switzerland | 2 | €157M |
| SpliceBio | Spain | 1 | €118M |
| Mironid | UK | 1 | €40M |
| Vivet Therapeutics | France | 1 | €38M |
| NMD Pharma | Denmark | 1 | €35M |
| MISSION Therapeutics | UK | 2 | €35M |
| DiogenX | France | 1 | €28M |
| Horizon Discovery | UK | 1 | €8.1M |
| MySugr | Austria | 1 | €4.3M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| SpliceBio | Series B | €118M | 2025-06 |
| GlycoEra | Series B | €114M | 2025-05 |
| GlycoEra | Series A | €43M | 2021-11 |
| Vivet Therapeutics | Series A | €38M | 2017-05 |
| NMD Pharma | Other | €35M | 2022-02 |
| DiogenX | Series A | €28M | 2023-05 |
| MISSION Therapeutics | Series B | €24M | 2013-11 |
| MISSION Therapeutics | Other | €11M | 2025-10 |
| Horizon Discovery | Series C | €8.1M | 2013-06 |
| MySugr | Series A | €4.3M | 2015-03 |